Close Menu

financial results

The firm reported preliminary revenues of $8.5 million for full-year 2020, which would beat the consensus Wall Street estimate of $8.0 million.

Diagnostics revenues were €32.5 million in Q3, up almost fivefold from €6.8 million last year, and included €27.4 million from commercial coronavirus testing.

For the three months ended Sept. 30, the Boulder, Colorado-based firm generated a revenue of $9.2 million, compared to $3.9 million year over year.

The company said the improvements it has made to its business during the pandemic will translate to significant increases in growth once it ends.

The company said clinical services revenues rose 66 percent during the quarter, driven by significant year-over-year growth in the volume of accessions.

For the three months ended Oct. 31, revenues rose to $1.48 billion from $1.37 billion in Q4 2019, beating the average Wall Street estimate of $1.4 billion.

The company reported total revenues of RMB123.9 million ($18.2 million) for the quarter, driven largely by growth in its central laboratory business.

Though its point-of-care revenues fell, the firm's clinical laboratory sales for the third quarter rose 44 percent over the prior-year quarter

The company said that it has received CE marks for two additional SARS-CoV-2 tests, including one that detects the virus and influenza A/B.

Life science product revenues nearly doubled, offsetting a continuing slide in the firm's diagnostics revenues.